MBA

Meijer Donation Supports Development of Michigan's First Children's Rehabilitation Hospital

Retrieved on: 
Monday, April 29, 2024
Cancer, Hospital, Hope, Partnership, Freedom, Children's Hospital, Patient, Rehabilitation hospital, Brain, MBA, Cerebral palsy, Organization

"As a family-owned company, we are humbled to give to organizations that provide hope and healing to so many families," Meijer President & CEO Rick Keyes said.

Key Points: 
  • "As a family-owned company, we are humbled to give to organizations that provide hope and healing to so many families," Meijer President & CEO Rick Keyes said.
  • "We're thrilled to be able to help Mary Free Bed and Helen DeVos Children's Hospital create the first children's rehabilitation hospital in Michigan and provide support to families in times of need."
  • The Joan Secchia Children's Rehabilitation Hospital will be a state-of-the-art, freestanding children's rehabilitation hospital dedicated to helping all kids achieve the best possible outcome through compassionate collaboration, innovation, and interdisciplinary care.
  • "This donation will uplift families, empower communities, and make a lasting impact for thousands of children for generations to come."

AF Group Announces Kriss Barronton as Chief Operating Officer

Retrieved on: 
Monday, April 29, 2024
Corporation, Car, Florida Atlantic University, University, Business transformation, AF Group, Risk management, Business, USAA, Atlantic University, Ward, MBA, Associate, Georgia State University, Management

LANSING, Mich., April 29, 2024 /PRNewswire/ -- AF Group has announced the appointment of Kriss Barronton as chief operating officer.

Key Points: 
  • LANSING, Mich., April 29, 2024 /PRNewswire/ -- AF Group has announced the appointment of Kriss Barronton as chief operating officer.
  • In her new role, Barronton will lead a number of key teams including Business Transformation, Loss Control, Premium Audit, Service Center and Corporate Underwriting.
  • Barronton joins AF Group, a Ward's 50 company for five years running and whose affiliate brands are premier providers of innovative, specialty insurance solutions nationwide.
  • "We're so pleased to welcome Kriss to our executive leadership team – and will certainly benefit from her significant experience and expertise in the industry," said Lisa Corless, president and CEO of AF Group.

Petauri™ Announces 2 Key Hires at Petauri Advisors

Retrieved on: 
Monday, April 29, 2024
CVS, University, Pharmacy, Amylin Pharmaceuticals, Mentorship, Care Act 2014, Pharmacist, Medicare Part D, Novartis, SVP, Pfizer, Senior, AMCP, Medicare, Marketing, MBA, Affordable Care Act, Pharmaceutical industry

NASHVILLE, Tenn., April 29, 2024 /PRNewswire/ -- Petauri Advisors, a strategic life sciences consulting business unit of Petauri, a leading purpose-built pharmaceutical services platform, announced today that it has added to its executive ranks 2 experienced leaders who bring extensive market access experience and expertise comprising implementation of Medicare Part D, the Affordable Care Act, and brand marketing.

Key Points: 
  • Petauri Advisors has added Gina Valerio and Joe Honcz to its ranks as VP and SVP, respectively.
  • Given her deep expertise in market access and brand marketing strategy, along with her profound understanding of the evolving healthcare landscape, Gina will be a highly valued partner to Petauri Advisors clients navigating today's market access challenges.
  • Before joining Petauri, Gina provided strategic market access consultative services to various pharmaceutical and life sciences companies in the San Diego area.
  • "With their proven track record across the continuum of managed care, Gina and Joe bring valuable and diverse experience to Petauri Advisors," said Steve O'Malley, President, Petauri Advisors.

BIOCARE, INC. APPOINTS NEW CHIEF EXECUTIVE OFFICER & CHIEF OPERATING OFFICER TO EXECUTIVE LEADERSHIP TEAM

Retrieved on: 
Monday, April 29, 2024
Stanford University, University, CFO, Certification, Partnership, History, Harvard Business School, Culture, CPA, Senior, Health, MBA, Division, Growth, Management

TEMPE, Ariz., April 29, 2024 /PRNewswire/ -- BioCare, a leading specialty pharmaceutical distribution partner comprised of BioCareSD and LogiCare3PL, today announced the appointment of James Frary as Chief Executive Officer (CEO) and Michael Kody as Chief Operating Officer (COO).  Linda Matthews, who has served as BioCare's CEO for over 25 years, will be retiring at the end of the year and will continue to serve as an advisor to the organization.

Key Points: 
  • TEMPE, Ariz., April 29, 2024 /PRNewswire/ -- BioCare, a leading specialty pharmaceutical distribution partner comprised of BioCareSD and LogiCare3PL , today announced the appointment of James Frary as Chief Executive Officer (CEO) and Michael Kody as Chief Operating Officer (COO).
  • "His partnership and dedication have been instrumental in driving our success, and I am excited about the future for BioCare under his leadership."
  • His distinguished background and exceptional leadership uniquely qualifies him to steer our operations and propel BioCare's ongoing growth and success."
  • Mr. Kody joins BioCare with over 20 years of diverse pharmaceutical leadership and extensive expertise in the healthcare sector.

Quincy Family Orthodontics Launches New Website to Enhance Patient Experience

Retrieved on: 
Monday, April 29, 2024
Blog, Harvard University, Health, Align Technology, Dentistry, Medicine, Family, GPA, Patient, Master, MBA, Orthodontics

QUINCY, Mass., April 29, 2024 /PRNewswire-PRWeb/ -- Quincy Family Orthodontics is excited to announce the launch of its new website, https://www.quincyfamilyortho.com, as well as its new office location at 300 Crown Colony Drive, Suite #205 in Quincy, MA.

Key Points: 
  • Quincy Family Orthodontics is excited to announce the launch of its new website, https://www.quincyfamilyortho.com , as well as its new office location at 300 Crown Colony Drive, Suite #205 in Quincy, MA.
  • QUINCY, Mass., April 29, 2024 /PRNewswire-PRWeb/ -- Quincy Family Orthodontics is excited to announce the launch of its new website, https://www.quincyfamilyortho.com , as well as its new office location at 300 Crown Colony Drive, Suite #205 in Quincy, MA.
  • At our clinic, the patient comes first – their health, comfort, and well-being drive everything we do.
  • Quincy Family Orthodontics offers traditional metal braces, ceramic braces, and Invisalign.

Ecopetrol announces senior management changes

Retrieved on: 
Saturday, April 27, 2024
Permian, Growth, Gulf of Mexico, Universidad Externado de Colombia, EPM, Behavior, Corporation, XM, Business administration, CESA, Universidad de los Andes, CHEC, Legislation, EAN, Advisory board, Sustainable Value, Transport, BVC, Connection, Marketing, ISA, Specialization, Commercial, Human resources, Trade, Human resource management, Acquisition, Marketing strategy, Telecommunications, MBA, Metro, Management

BOGOTA, Colombia, April 26, 2024 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) announces that the Board of Directors, at its meeting held on April 26, 2024, made the following appointments in property:

Key Points: 
  • BOGOTA, Colombia, April 26, 2024 /PRNewswire/ -- Ecopetrol S.A. (BVC: ECOPETROL; NYSE: EC) announces that the Board of Directors, at its meeting held on April 26, 2024, made the following appointments in property:
    1.
  • He has 25 years of experience in commercial and marketing positions, 20 of which have been in Ecopetrol in the areas of marketing, commercialization, evaluation and structuring of new businesses.
  • Ecopetrol S.A. thanks Alberto for his valuable management during more than seven years in the Ecopetrol Group.
  • Ecopetrol is the largest company in Colombia and one of the main integrated energy companies in the American continent, with more than 18,000 employees.

EQS-News: Resolutions of the 80th Annual General Meeting of Lenzing AG

Retrieved on: 
Friday, May 3, 2024
Annual, Remuneration, Lenzing, AG, Mass meeting, Mag, Supervisory board, Lenzing AG, Supervision, Bank statement, MBA, Property management

Lenzing – On Thursday, April 18, 2024, the 80th Annual General Meeting of Lenzing AG discharged the members of the Managing Board and the Supervisory Board for the 2023 financial year and set the remuneration of the members of the Supervisory Board for the 2024 financial year in advance.

Key Points: 
  • Lenzing – On Thursday, April 18, 2024, the 80th Annual General Meeting of Lenzing AG discharged the members of the Managing Board and the Supervisory Board for the 2023 financial year and set the remuneration of the members of the Supervisory Board for the 2024 financial year in advance.
  • The General Meeting elected Dr. Cornelius Baur as a new member of the Supervisory Board of Lenzing AG until the end of the General Meeting that decides on the discharge for the 2028 financial year.
  • The Supervisory Board of Lenzing AG continues to consist of ten members elected by the Annual General Meeting: Dr. Cornelius Baur, Mag.
  • In the constitutive meeting of the Supervisory Board following the Annual General Meeting, Cord Prinzhorn, MBA, was elected Chairman and Dr. Stefan Fida was re-elected as Deputy Chairman of the Supervisory Board.

EQS-News: CureVac Announces Financial Results for the Fourth Quarter and Full-Year 2023 and Provides Business Update

Retrieved on: 
Friday, May 3, 2024
University, Part, CMO, Federal republic, Research, Cancer, Federal Patent Court (Germany), Vaccine, Business, Webcast, BioNTech, District court, Whole genome sequencing, Vaccination, Public, WHO, Hearing loss, Cardiology, Animal, EP 1, Omicron, GSK, Systems biology, Workforce, Infection, Messenger, Federal court, Therapy, Data monitoring committee, Safety, Monroe Dunaway Anderson, CVAC, Justice, RNA, Astrocytoma, Motion, Human, CureVac, Pandemic, GMP, Sąd rejonowy, SARS-CoV-2, Business development, Epitope, MD, Acuitas Therapeutics, DSMB, Ageing, Patent, Patient, Neurology, Operating cost, H5N1, MD Anderson Cancer Center, PPA, Interim, MBA, Antigen, COVID-19, Amgen

ET / 3 p.m. CET

Key Points: 
  • ET / 3 p.m. CET
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 – CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced financial results for the fourth quarter and full-year 2023 and provided a business update.
  • “We closed out 2023 on a sturdy footing and are poised to advance strongly through 2024 with strategic initiatives to make CureVac fit-for-purpose.
  • Thaminda Ramanayake was appointed to the CureVac Management Team as Chief Business Officer effective June 1, 2024.
  • Mr. Ramanayake joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.

EQS-News: CureVac Appoints Thaminda Ramanayake as New Chief Business Officer

Retrieved on: 
Friday, May 3, 2024
University, Berea College, Hearing loss, Cardiology, CVAC, Johnson & Johnson, Business development, Research, Business, CureVac, Neurology, Systems biology, Infection, Messenger, MBA, Therapy, Amgen, Pharmaceutical industry

Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas

Key Points: 
  • Strong track record of successful clinical collaborations, M&A, asset in-licensing and strategic financing initiatives across multiple therapeutic areas
    TÜBINGEN, Germany/BOSTON, USA – April 24, 2024 — CureVac N.V. (Nasdaq: CVAC) (“CureVac”), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced that Thaminda Ramanayake has been appointed to the role of Chief Business Officer, effective June 1, 2024.
  • “Thaminda’s extensive experience in advancing corporate strategy, business development and strengthening strategic partnerships in specific areas will be a tremendous asset to CureVac as we work to progress best-in-class mRNA vaccines and medicines across multiple therapeutic areas,” said Dr. Alexander Zehnder, Chief Executive Officer of CureVac.
  • He joins CureVac from Affini-T Therapeutics, where he served as Chief Business Officer and was responsible for creating the company’s business development organization.
  • With an educational background in both immunology and business, Mr. Ramanayake began his career as a scientist at Johnson & Johnson and later held a succession of Wall Street business development and consulting roles.

EQS-News: BIRKENSTOCK ANNOUNCES MEGAN KULICK AS DIRECTOR INVESTOR RELATIONS

Retrieved on: 
Friday, May 3, 2024
Telecommunications, University, JPMorgan Chase, Equity, Language, Nature, Zeitgeist, Geography, Telephone, Merrill (company), Business administration, Research, Foot, PIMCO, Senior, Street, MBA, Walking, Cresco Labs

LONDON, UNITED KINGDOM || APRIL 16, 2024

Key Points: 
  • LONDON, UNITED KINGDOM || APRIL 16, 2024
    Birkenstock Holding plc (“BIRKENSTOCK” or the “Company”, NYSE: BIRK), announced today the appointment of Megan Kulick to Director Investor Relations, effective April 15, 2024.
  • Based in New York, Ms. Kulick will report to the Board of Directors of the Company.
  • Birkenstock Holding plc is the ultimate parent company of Birkenstock Group B.V. & Co. KG and its subsidiaries (the "Birkenstock Group").
  • BIRKENSTOCK is the inventor of the footbed and has shaped the principle of walking as intended by nature ("Naturgewolltes Gehen").